News
SGHT
5.34
-8.09%
-0.47
Weekly Report: what happened at SGHT last week (0506-0510)?
Weekly Report · 6d ago
Sight Sciences, Inc. 10-Q Report: Financial Condition and Results of Operations
Press release · 05/06 22:11
Weekly Report: what happened at SGHT last week (0429-0503)?
Weekly Report · 05/06 09:11
A US$34m Market Cap Boost Pleasing ToSight Sciences Insiders
Sight Sciences, Inc. Insiders bought US$34m worth of shares in the last 12 months. The company's market value increased by 13% over the same period. Chairman Staffan Encrantz made the biggest insider purchase of the last year. Sight Sciences owns 22% of the company. In the last three months, Sight Sciences insiders sold US$173k worth of stock. You should pay attention to the insider transactions at Sight Sciences.
Simply Wall St · 05/04 12:27
Sight Sciences Inc reports results for the quarter ended in March - Earnings Summary
Sight Sciences Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 33 cents per share. Revenue rose 2.3% to $19.27 million from a year ago. Sight Sciences Inc shares had risen by 6.3%.
Reuters · 05/03 19:36
Sight Sciences GAAP EPS of $0.33, revenue of $19.3M
Seeking Alpha · 05/03 15:06
Sight Sciences Price Target Raised to $6.00/Share From $5.00 by Piper Sandler
Dow Jones · 05/03 13:50
Piper Sandler Reiterates Neutral on Sight Sciences, Raises Price Target to $6
Benzinga · 05/03 13:40
Piper Sandler Sticks to Their Hold Rating for Sight Sciences (SGHT)
TipRanks · 05/03 12:18
SIGHT SCIENCES INC <SGHT.O>: CITIGROUP RAISES TARGET PRICE TO $6 FROM $5.5
Reuters · 05/03 10:38
Needham Reiterates Hold on Sight Sciences
Benzinga · 05/03 09:55
Needham Remains a Hold on Sight Sciences (SGHT)
TipRanks · 05/03 09:17
U.S. RESEARCH ROUNDUP- Paramount Global, Sprout Social, Williams-Sonoma
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Paramount Global, Sprout Social, Williams-Sonoma and Expedia Group among those. Apple, Amgen and Amgen raise their targets for the day. Apple raises its target price to $225 from $200.
Reuters · 05/03 07:04
SGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024
Sight Sciences reported results for the first quarter of 2024. Sight Sciences reported earnings per share of -33 cents. The company reported revenue of $19.27 million. This was 4.82% better than the analyst estimate for revenue of -18.8 million.
Investorplace · 05/03 01:55
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 05/02 22:20
Sight Sciences Q1 2024 GAAP EPS $(0.33) Misses $(0.30) Estimate, Sales $19.265M Beat $18.382M Estimate
Sight Sciences (NASDAQ:SGHT) reported quarterly losses of $0.33 per share. The company reported quarterly sales of $19.265 million which beat the analyst consensus estimate of $18.382 million. Sight Sciences missed the analyst estimate by 10 percent.
Benzinga · 05/02 21:23
Sight Sciences Enhances Transparency with Strategic Financial Moves
TipRanks · 05/02 20:25
*Sight Sciences Backs FY24 Rev $81M-$85M >SGHT
Dow Jones · 05/02 20:15
*Sight Sciences 1Q Loss/Shr 33c >SGHT
Dow Jones · 05/02 20:14
*Sight Sciences Reaffirms Full Yr 2024 Fincl Guidance
Dow Jones · 05/02 20:14
More
Webull provides a variety of real-time SGHT stock news. You can receive the latest news about Sight Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGHT
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.